中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

158 records (took 0.025 seconds)

    Procoagulant compounds
    72.
    发明授权
    Procoagulant compounds 有权

    公开(公告)号：US11261437B2

    公开(公告)日：2022-03-01

    申请号：US16357153

    申请日：2019-03-18

    Applicant: Bioverativ Therapeutics Inc.

    Inventor： Vu Phong Hong ,  Adam R. Mezo ,  Joe Salas ,  Robert Peters

    IPC: C12N9/64 ,  A61K47/62 ,  A61K38/36 ,  A61K38/48 ,  A61K38/02

    Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.

    FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF
    73.
    发明申请
    FACTOR VIII COMPLEX WITH XTEN AND VON WILLEBRAND FACTOR PROTEIN, AND USES THEREOF 有权

    公开(公告)号：US20220056108A1

    公开(公告)日：2022-02-24

    申请号：US17358142

    申请日：2021-06-25

    Applicant: Bioverativ Therapeutics Inc.

    Inventor： Ekta Seth CHHABRA ,  Tongyao LIU ,  Pei-yun CHANG ,  Robert T. PETERS ,  John KULMAN ,  Haiyan JIANG

    IPC: C07K14/755 ,  A61K47/55 ,  A61K38/36 ,  A61K38/37 ,  C07K16/00 ,  C12N15/11

    Abstract: The present invention provides a chimeric protein comprising a VWF protein comprising the D′ domain and D3 domain of VWF, one or more XTEN sequence, and a FVIII protein, wherein the VWF fragment, the XTEN sequence, or the FVIII protein are linked to or associated with each other. The chimeric protein can further comprise one or more Ig constant region or a portion thereof (e.g., an Fc region). A polypeptide chain comprising a VWF fragment of the invention binds to or is associated with a polypeptide chain comprising a FVIII protein linked to an XTEN sequence and the polypeptide chain comprising the VWF fragment can prevent or inhibit binding of endogenous VWF to the FVIII protein linked to the XTEN sequence. By preventing or inhibiting binding of endogenous VWF to the FVIII protein, which is a half-life limiting factor for FVIII, the VWF fragment can induce extension of half-life of the chimeric protein comprising a FVIII protein. The invention also includes nucleotides, vectors, host cells, methods of using the VWF fragment, or the chimeric proteins.

    Chimeric clotting factors
    76.
    发明授权
    Chimeric clotting factors 有权

    公开(公告)号：US11168316B2

    公开(公告)日：2021-11-09

    申请号：US16228144

    申请日：2018-12-20

    Applicant: Bioverativ Therapeutics Inc.

    Inventor： Joe Salas ,  Elena Kistanova ,  Vu Phong Hong ,  Adam R. Mezo ,  Robert T. Peters

    IPC: C12N9/64 ,  A61K47/62 ,  A61K38/36 ,  A61K38/48

    Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.

Patent Agency Ranking